Summary and Notable Findings:
- 332 samples were analyzed between April 1 and June 30, 2025.
- Fentanyl adulteration is shifting—for alpha-2 agonists, in favor of medetomidine over xylazine, and with local anesthetics (e.g., lidocaine, procaine, tetracaine) increasing in prevalence.
- Novel synthetic opioids continue to appear—nitazene analogues were infrequently detected in quarter, while fentanyl analogues (e.g., carfentanil, para-fluorofentanyl) were more common.
- Observations of BTMPS have decreased from Q1 to Q2 2025.
- MDMA (n=6) was observed more than NPS simulants (n=1).
- Synthetic cannabinoids 5F-ADB (n=2) and MDMB-4en-PINACA (n=4) were detected among K2/Spice suspected samples.
- The CFSRE is validating an expanded quantitative test panel to include more drugs and adulterants than previously quantifiable. Updated quantitative results will follow in future quarterly reports.
- The CFSRE has implemented a customized data and information management system, which enables effective and efficient sample tracking, testing, reporting, and data analysis.
